Examkin

Question

Difficulty: HardRheumatology and Immunology

Match each clinical scenario describing a medication-specific toxicity, mechanism, or required screening protocol to the appropriate disease-modifying medication used in rheumatologic conditions.

  • A 34-year-old woman develops progressive paracentral scotomas and impaired color vision after 7 years of maintenance therapy for systemic lupus erythematosus.Hydroxychloroquine
  • A 28-year-old woman with severe rheumatoid arthritis is started on a pyrimidine synthesis inhibitor; she is advised that an accelerated drug elimination procedure with cholestyramine will be mandatory if she wishes to conceive.Leflunomide
  • A 45-year-old man receiving induction therapy for severe lupus nephritis develops gross hematuria. Cystoscopy reveals a bladder complication caused by the toxic metabolite acrolein.Cyclophosphamide
  • A 31-year-old man with ankylosing spondylitis is evaluated for a new biologic therapy; pre-treatment screening reveals a positive interferon-gamma release assay, necessitating prophylactic treatment for latent infection.Adalimumab
  • A 50-year-old woman with systemic vasculitis is considered for steroid-sparing therapy; prior to initiation, genetic testing for a specific methyltransferase enzyme deficiency is ordered to prevent predictable, life-threatening myelosuppression.Azathioprine

Answer

1 matches Hydroxychloroquine (maculopathy); 2 matches Leflunomide (cholestyramine washout); 3 matches Cyclophosphamide (acrolein-induced cystitis); 4 matches Adalimumab (TB reactivation); 5 matches Azathioprine (TPMT screening).
Proper management of rheumatologic conditions requires intimate knowledge of drug toxicities. Hydroxychloroquine causes dose-dependent retinopathy. Leflunomide inhibits pyrimidine synthesis and requires cholestyramine washout due to severe teratogenicity and a long half-life. Cyclophosphamide's metabolite acrolein causes hemorrhagic cystitis, preventable with mesna. Adalimumab, a TNF-alpha inhibitor, disrupts granulomas and risks TB reactivation. Azathioprine metabolism depends on TPMT, necessitating genetic screening to prevent fatal bone marrow suppression.

Step-by-Step Solution

1
Analyze each clinical vignette to identify the signature adverse effect, mechanism, or prerequisite screening requirement being described.
Identified toxicities/protocols: maculopathy/vision changes, teratogenicity requiring active washout, acrolein-induced hemorrhagic cystitis, latent tuberculosis reactivation, and TPMT-related myelosuppression.
Recognizing the signature side effects and monitoring requirements is essential for safely managing immunomodulatory therapies.
2
Correlate these clinical clues with the known pharmacologic profiles of common rheumatologic medications.
Maculopathy maps to hydroxychloroquine; the pyrimidine inhibitor requiring washout is leflunomide; acrolein toxicity maps to cyclophosphamide; TNF-alpha inhibition causing TB reactivation maps to adalimumab; and TPMT metabolism maps to azathioprine.
Matching the distinct pharmacologic characteristics to the clinical scenarios ensures accurate identification of the responsible disease-modifying antirheumatic drugs (DMARDs).

Key Concept

Monitoring requirements and adverse effect profiles of disease-modifying antirheumatic drugs (DMARDs) and immunosuppressants.
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic